logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

“Spanish society should know that participating in a clinical trial is something beneficial”

Farmaindustria participates in the program ‘Es la Tarde de Dieter’, by EsRadio, in a debate on clinical research in Spain

Source: www.farmaindustria.es

Clinical trials, which are the studies that determine the safety and efficacy of a new drug for authorization, have great value for all agents in the healthcare chain: for patients, who thanks to them can access innovative medicines from early form, which is sometimes the only therapeutic option available; for health professionals, who by virtue of their participation in the trials see their knowledge updated and complement their care work with research activity, and for the laboratories themselves, who need to develop trials, keys to demonstrate the efficacy and safety of new medicines , in a quality environment.

These studies also stimulate the biomedical R & D of the health systems that attract them and generate an important economic flow for hospitals and participating centers, since both innovative medication and all expenses related to diagnosis and treatment are borne by the promoter company, which manages to culminate the efforts made in the preclinical phases and move forward to achieve the authorization of the medicine.

Spain is today one of the countries with the best conditions to host clinical trials, since it has “an excellent National Health System, health professionals with high scientific level and very committed to research and an increasingly active group of patients”, without forgetting the support of the Spanish Agency for Medicines and Health Products and a favorable legal framework, as highlighted by Amelia Martín Uranga, responsible for the Plataforma de Medicamentos Innovadores de Farmaindustria.

Martín Uranga, who participated on Tuesday in the program Es la tarde de Dieter, by EsRadio, considered that today “in Spain there is a lot of research and good” due, among other factors, to the success of public-private collaboration formulas. “There is no other way to do it” -he added- if we consider that making a medicine available to patients is very complex (the R & D process takes between 10 and 12 years), costly (more than 2,400 million euros) ) and risky, since only one of every 10,000 molecules that are being investigated has become an authorized medicine.

In the debate, in which the director of the Health Research Institute of the Fundación Jiménez Díaz University Hospital, Carmen Ayuso, also participated, the representative of Farmaindustria pointed out that there are, nevertheless, aspects that can be improved, such as excessive bureaucracy to start up a clinical trial or patient recruitment.

“There are centers that always have 10% of patients who have not recruited, and there we all lose: the patient who does not enter, so that many times that trial is the only therapeutic alternative, and the rest of the agents involved: the researcher, the Spanish Agency for Medicines and Health Products and the industry. We have to get to the maximum number of patients in the trials because that is how we will all win. ”

For this, in the opinion of the representative of Farmaindustria, it is important that patient organizations collaborate and “society knows that participating in a trial is something beneficial”, and also that the authorities are aware of the effort of industry and research teams. public and private centers for making available to patients those medications capable of changing their lives because they are disruptive and capable of modifying the course of the disease; that they are aware, in short, of the social value of the medicine “.

From Distefar we add to the importance of letting patients know that participating in clinical trials is beneficial for them and the whole society.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.